1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Competitor Analysis: CD19-Targeted Therapeutics

Competitor Analysis: CD19-Targeted Therapeutics

  • October 2013
  • -
  • La Merie Publishing
  • -
  • 34 pages

Renewed interest in CD19 as target for antibody and T-cell Therapeutics

The human CD19 antigen is a 95 kd transmembrane glycoprotein. It is specifically expressed in normal and neoplastic B cells, as well as follicular dendritic cells. CD19 serves as a diagnostic marker for B-cell malignancies. Virtually all cases of acute lymphoblastic leukemia (ALL) are CD19 positive. Years ago, naked antibodies have been generated against CD19, but clinical results were not sufficiently satisfactory. With the advent of new technologies to increase effector funtions of antibodies and to engineer cytotoxic T-lymphocytes to redirect them to CD19, this target has regained considerably interest in oncology.


The present Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment of B-cell hematologic malignancies as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


The report includes a compilation of currently active projects in research and development of antibodies and T-cells targeting CD19 and with enhanced effector fucntion. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on:


-Drug Codes,
-Target / Mechanism of Action,
-Class of Compound,
-Company,
-Product Category,
-Indication,
-R&D Stage and
-additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: CD19-Targeted Therapeutics
Competitor Analysis: CD19-Targeted Therapeutics

Table of Contents


-Fc-Engineered CD19-Targeted Monoclonal Antibodies
-CD19-Targeted Antibody-Drug Conjugates
-CD19-Targeted Immunotoxin          
-Bispecific, CD19-Targeted and T-Cell Redirecting Monoclonal Antibodies
-Autologous CD19-Targeted T-Cells
-Allogeneic CD19-Targeted T-Cells
-Corporate and Academic CD19-Targeted Therapeutics Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017-2021 Emerging Opportunities in the Cell Surface Markers: US, Europe (France, Germany, Italy, Spain, UK), Japan--Emerging Opportunities, Country Forecasts, Innovative Technologies, and Competitive Landscape

2017-2021 Emerging Opportunities in the Cell Surface Markers: US, Europe (France, Germany, Italy, Spain, UK), Japan--Emerging Opportunities, Country Forecasts, Innovative Technologies, and Competitive Landscape

  • $ 3500
  • Industry report
  • February 2017
  • by Venture Planning Group

The use of surface marker identification and classification of cells is spreading beyond lymphocytes to the identification of monocytes, macrophages, myeloid stem cells, and tumor cells. A synergistic ...

Global Single Cell Analysis Market Analysis & Trends - Industry Forecast to 2025

Global Single Cell Analysis Market Analysis & Trends - Industry Forecast to 2025

  • $ 4200
  • Industry report
  • January 2017
  • by Accuray Research LLP

The Global Single Cell Analysis Market is poised to grow at a CAGR of around 18.9% over the next decade to reach approximately $6.92 billion by 2025. Some of the prominent trends that the market is witnessing ...

2017-2021 Cell Surface Markers: US, Europe (France, Germany, Italy, Spain, UK), Japan--Competitive Strategies, Country Forecasts, Innovative Technologies, Emerging Opportunities

2017-2021 Cell Surface Markers: US, Europe (France, Germany, Italy, Spain, UK), Japan--Competitive Strategies, Country Forecasts, Innovative Technologies, Emerging Opportunities

  • $ 3500
  • Industry report
  • January 2017
  • by Venture Planning Group

The use of surface marker identification and classification of cells is spreading beyond lymphocytes to the identification of monocytes, macrophages, myeloid stem cells, and tumor cells. A synergistic ...


Download Unlimited Documents from Trusted Public Sources

Biological Therapy Industry in the US

  • February 2017
    11 pages
  • Biological Ther...  

    Biotechnology  

  • United States  

    United Kingdom  

View report >

Biological Therapy Industry in the US

  • February 2017
    7 pages
  • Biological Ther...  

    Biotechnology  

  • United States  

View report >

DNA Industry

  • February 2017
    12 pages
  • DNA  

View report >

Related Market Segments :

Hospital

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.